mRNA-3927

DB17669InvestigationalNucleic Acid Based Therapies

mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid... Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.

Mechanism: Pharmacologically active on Propionyl-CoA carboxylase alpha chain, mitochondrial and Propionyl-CoA carboxylase beta chain, mitochondrial
Curator reviewed
Code names: mRNA-3927

Resolves to

Targets

P05165PCCAP05166PCCB

What you can answer from here — as of September 25, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with mRNA-3927, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account